Difficulty: Medium
Average Score: 84%
Practice
Blinatumomab, a bispecific T-cell engaging molecule, is active against which CD antigen that is expressed on B-lymphoblasts?
Correct answer
C
Rationale
Step-by-step rationale:
1. Blinatumomab is a bispecific molecule designed to engage T-cells to target B-lymphoblasts.
2. It targets CD19, a B-cell-specific antigen expressed on B-lymphoblasts.
3. Engagement of T-cells via CD19 leads to targeted killing of B-lymphoblasts.
4. CD10, CD15, and CD20 are not specific to B-cells, making them incorrect choices.
Summary:
The correct answer is C (CD19) because blinatumomab's mechanism of action specifically targets B-lymphoblasts via CD19. Choices A, B, and D are incorrect as they do not have the same specificity for B-cells as CD19 does.
1. Blinatumomab is a bispecific molecule designed to engage T-cells to target B-lymphoblasts.
2. It targets CD19, a B-cell-specific antigen expressed on B-lymphoblasts.
3. Engagement of T-cells via CD19 leads to targeted killing of B-lymphoblasts.
4. CD10, CD15, and CD20 are not specific to B-cells, making them incorrect choices.
Summary:
The correct answer is C (CD19) because blinatumomab's mechanism of action specifically targets B-lymphoblasts via CD19. Choices A, B, and D are incorrect as they do not have the same specificity for B-cells as CD19 does.